financetom
Business
financetom
/
Business
/
American Bitcoin, backed by Trump's sons, aims to start trading in September
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
American Bitcoin, backed by Trump's sons, aims to start trading in September
Aug 27, 2025 11:56 PM

HONG KONG (Reuters) -American Bitcoin, the bitcoin miner backed by U.S. President Donald Trump's two sons, has locked in crypto and traditional investors to back an all-stock merger that will allow the firm to soon start trading on the Nasdaq, the company's largest investor said.

The unlisted firm's merger with Gryphon Digital Mining ( GRYP ) is set to be finalised shortly, and the goal is to start trading in early September, according to Asher Genoot, the CEO of Hut 8 ( HUT ), which holds 80% of American Bitcoin.

Anchor shareholders in the listing have already been finalised, he added.

The company's co-founder, Eric Trump, his brother Donald Trump Jr and Hut 8 ( HUT ), will own a combined 98% of the newly formed entity, which will retain the name American Bitcoin and trade under the stock code ABTC.

"Instead of going public directly via IPO, we thought that there was a lot more advantages to financing if we had an existing company that already had access to different financing too," Genoot told Reuters in an interview at the Crypto Asia conference in Hong Kong.

Eric Trump is also in Hong Kong and will travel to Tokyo on the weekend for an event for Metaplanet, a Japanese bitcoin treasury firm, Genoot said.

American Bitcoin is hunting for crypto assets to buy in Hong Kong and Japan to build out its global business, the Financial Times reported two weeks ago.

Genoot said American Bitcoin could take stakes in companies outside of the U.S. to give people access to publicly listed bitcoin assets, as some investors were prevented from buying Nasdaq-listed stocks.

"Right now it's very early. So we haven't been committed to anything," he said.

Hut 8 ( HUT ) was also a crypto miner but has shifted its focus to energy infrastructure and data centers after launching American Bitcoin with Trump sons, he added.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Market Chatter: American Airlines Reportedly Attempting to Delay Resumption of 2 China Flights
Market Chatter: American Airlines Reportedly Attempting to Delay Resumption of 2 China Flights
Sep 21, 2024
12:03 PM EDT, 09/20/2024 (MT Newswires) -- American Airlines Group ( AAL ) is seeking to delay the resumption of two daily flights from the US to China due to sluggish demand, Reuters reported Friday. American Airlines ( AAL ) has requested the US Transportation Department's approval to extend a waiver to continue the suspension of the daily flights to...
US FDA approves AstraZeneca's flu vaccine for self-administration
US FDA approves AstraZeneca's flu vaccine for self-administration
Sep 21, 2024
(Reuters) - The U.S. Food and Drug Administration said on Friday it has approved AstraZeneca's ( AZN ) influenza nasal spray vaccine for self-administration, making it the first of its kind that patients can give themselves. FluMist is the first vaccine to prevent influenza that does not need to be administered by a healthcare provider, the regulator said. The flu...
--Street Color: CVS, Cigna, UnitedHealth Units Sued by FTC for Allegedly Inflating Insulin Prices
--Street Color: CVS, Cigna, UnitedHealth Units Sued by FTC for Allegedly Inflating Insulin Prices
Sep 21, 2024
12:21 PM EDT, 09/20/2024 (MT Newswires) -- Price: 57.44, Change: -0.96, Percent Change: -1.65 ...
Novo Nordisk Stock Declines After Headline Results From Mid-Stage Study Of Monlunabant In Obese Patients
Novo Nordisk Stock Declines After Headline Results From Mid-Stage Study Of Monlunabant In Obese Patients
Sep 21, 2024
Friday, Novo Nordisk A/S ( NVO ) announced headline results from a phase 2a clinical trial with monlunabant, a small-molecule oral cannabinoid receptor 1 (CB1) inverse agonist. Monlunabant, formerly INV-202, was part of the acquisition of Inversago Pharmaceuticals Inc. for $1.075 billion, announced in August 2023. Also Read: European Drug Agency Supports Novo Nordisk’s Blockbuster Weight-Loss Drug Wegovy For Obesity-Related...
Copyright 2023-2026 - www.financetom.com All Rights Reserved